Literature DB >> 10469672

Low molecular weight heparin (enoxaparin) in the management of unstable angina: the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.

K A Fox1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10469672      PMCID： PMC1766504          DOI： 10.1136/hrt.82.2008.i12

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  8 in total

1.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

Authors:  M Cohen; C Demers; E P Gurfinkel; A G Turpie; G J Fromell; S Goodman; A Langer; R M Califf; K A Fox; J Premmereur; F Bigonzi
Journal:  N Engl J Med       Date:  1997-08-14       Impact factor: 91.245

2.  Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.

Authors:  A Oler; M A Whooley; J Oler; D Grady
Journal:  JAMA       Date:  1996-09-11       Impact factor: 56.272

3.  Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

Authors:  W Klein; A Buchwald; S E Hillis; S Monrad; G Sanz; A G Turpie; J van der Meer; E Olaisson; S Undeland; K Ludwig
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

4.  Aspirin, heparin, or both to treat acute unstable angina.

Authors:  P Théroux; H Ouimet; J McCans; J G Latour; P Joly; G Lévy; E Pelletier; M Juneau; J Stasiak; P deGuise
Journal:  N Engl J Med       Date:  1988-10-27       Impact factor: 91.245

5.  Reactivation of unstable angina after the discontinuation of heparin.

Authors:  P Théroux; D Waters; J Lam; M Juneau; J McCans
Journal:  N Engl J Med       Date:  1992-07-16       Impact factor: 91.245

6.  Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators.

Authors:  S Yusuf; M Flather; J Pogue; D Hunt; J Varigos; L Piegas; A Avezum; J Anderson; M Keltai; A Budaj; K Fox; L Ceremuzynski
Journal:  Lancet       Date:  1998-08-15       Impact factor: 79.321

7.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.

Authors:  H D Lewis; J W Davis; D G Archibald; W E Steinke; T C Smitherman; J E Doherty; H W Schnaper; M M LeWinter; E Linares; J M Pouget; S C Sabharwal; E Chesler; H DeMots
Journal:  N Engl J Med       Date:  1983-08-18       Impact factor: 91.245

8.  Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.

Authors:  M Cohen; P C Adams; G Parry; J Xiong; D Chamberlain; I Wieczorek; K A Fox; J H Chesebro; J Strain; C Keller
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690
  8 in total
  1 in total

1.  Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome.

Authors:  Max Brosa; Carlos Rubio-Terrés; Ibrahim Farr; Vijay Nadipelli; Jenaro Froufe
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.